People · Operator
Named in public records as an officer, director or promoter · active 2013–2021 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. | — | Biotechnology | Series D+ | $163.4M | $4.0B | 2021 |
| Femasys Inc | — | Biotechnology | Series B | $74.7M | $32.0M | 2016 |
| ADVANCE Medical, Ltd. | — | Other | Series B | $19.8M | $328.1M | 2013 |
Fred Aslan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fred Aslan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Bryan Roberts | 1 | 18 |
| Joshua Silverman | 1 | 8 |
| Charles Larsen | 1 | 7 |
| John Adams | 1 | 6 |
| Paul McCreadie | 1 | 6 |
| Parker H. Petit | 1 | 5 |
| Gary Thompson | 1 | 4 |
| Darren Hite | 1 | 3 |
| DOV ELEFANT | 1 | 3 |
| John Dyett | 1 | 3 |
| Thomas J. Farrell | 1 | 2 |
| Max Azevedo | 1 | 1 |
| Jeffrey Marcus | 1 | 1 |
| Jeffrey A. Marcus | 1 | 1 |
| Daniel Currie | 1 | 1 |
| Kathy Lee-Sepsick | 1 | 1 |
| Marc Finch | 1 | 1 |
| Edward Uzialko | 1 | 1 |
| Lisa Peacock | 1 | 1 |
| Edward R. Uzialko, Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.